Literature DB >> 15328133

Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.

Issam I Raad1, Hend A Hanna, Ray Y Hachem, Tanya Dvorak, Rebecca B Arbuckle, Gassan Chaiban, Louis B Rice.   

Abstract

The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328133      PMCID： PMC514771          DOI： 10.1128/AAC.48.9.3583-3585.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.

Authors:  S K Fridkin; C D Steward; J R Edwards; E R Pryor; J E McGowan; L K Archibald; R P Gaynes; F C Tenover
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

Authors:  S H Marshall; C J Donskey; R Hutton-Thomas; R A Salata; L B Rice
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe.

Authors:  M Soltani; D Beighton; J Philpott-Howard; N Woodford
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

5.  Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.

Authors:  P K Linden; R C Moellering; C A Wood; S J Rehm; J Flaherty; F Bompart; G H Talbot
Journal:  Clin Infect Dis       Date:  2001-10-19       Impact factor: 9.079

6.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.

Authors:  D J Winston; C Emmanouilides; A Kroeber; J Hindler; D A Bruckner; M C Territo; R W Busuttil
Journal:  Clin Infect Dis       Date:  2000-05-18       Impact factor: 9.079

8.  Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

Authors:  I Raad; R Hachem; H Hanna; E Girgawy; K Rolston; E Whimbey; R Husni; G Bodey
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.

Authors:  Michael Lobritz; Rebecca Hutton-Thomas; Steve Marshall; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079
View more
  16 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

4.  Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.

Authors:  Jamela Seedat; Günther Zick; Ingo Klare; Carola Konstabel; Norbert Weiler; Hany Sahly
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

5.  Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.

Authors:  Marc H Scheetz; Stephanie A Knechtel; Michael Malczynski; Michael J Postelnick; Chao Qi
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

6.  Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.

Authors:  Heather B Jaspan; Adam W Brothers; Angela J P Campbell; John K McGuire; Samuel R Browd; Thomas J Manley; Daniel Pak; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

7.  Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium.

Authors:  Konstantinos Pontikis; Angelos Pefanis; Thomas Tsaganos; Ira-Maria Tzepi; Dionyssia-Pinelopi Carrer; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

8.  Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium.

Authors:  B Schulte; A Heininger; I B Autenrieth; C Wolz
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

9.  Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis.

Authors:  Chao Qi; Xiaotian Zheng; Arlene Obias; Marc H Scheetz; Michael Malczynski; John R Warren
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Virulence of vancomycin-resistant Enterococcus faecium according to linezolid resistance and clinical outbreak status.

Authors:  Milena McLaughlin; Michael Malczynski; Chao Qi; Grace Barajas; Jordan Radetski; Teresa Zembower; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.